ArticleBiochemistry and biophysics reports2025
Alterations of renal polyamine metabolism in mice with folic acid-induced chronic kidney disease.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) often follows acute kidney injury, leading to renal fibrosis and progressive renal failure. Spermine, a polyamine with antioxidant and anti-inflammatory properties, helps reduce renal fibrosis and may serve as a biomarker for CKD progression. We used spatially resolved metabonomic analysis with AFADESI-MSI to examine polyamine distribution in kidneys of a folic acid (FA)-induced CKD mouse model. Results showed decreased spermine and increased spermidine levels, associated with elevated spermine oxidase (SMOX) and spermidine/spermine N1-acetyltransferase (SSAT) enzyme expression in CKD. These findings suggest that altered polyamine metabolism contributes to CKD progression and may provide targets for polyamine-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.